Fluorescence lifetime platform for robust drug screening

TTP Labtech and Almac Group have formed a strategic partnership to bring a fully integrated fluorescence lifetime platform. The new platform comprises TTP Labtech’s new ameon lifetime reader and Almac’s FLEXYTE lifetime assays and reagents for precise lifetime assays, to provide a simple one-stop shop for robust, cost-effective drug screening and profiling.

The reader can be combined with FLEXYTE lifetime reagents for the screening of common drug targets such as protein kinases and proteases, as well as challenging epigenetic targets.

Applying such a powerful combination allows researchers to reduce compound-related assay interference, select fewer false leads and obtain the reliability normally associated with biophysical methods at the compound screen stage.

Recent Issues